Each enteric coated tablet contains: Aspirin 100 mg.
Aspirin is a salicylate NSAID and has many properties in common with non-aspirin NSAIDs. It has analgesic, anti-inflammatory and antipyretic properties; it has inhibitor of the enzyme cyclooxygenase, which results in the direct inhibition of the biosynthesis of prostaglandin and thromboxanes from arachidonic acid. Aspirin also inhibits platelet aggregation; non-acetylated salicylates do not.
Pharmacology: Pharmacokinetics: Aspirin and other salicylates are absorbed rapidly from the gastrointestinal tract but absorption following rectal administration is less reliable than after oral administration. Aspirin and other salicylates can also be absorbed through the skin.
Following oral administration, absorption of non-ionised aspirin occurs in the stomach and intestine. Some aspirin is hydrolysed to salicylate in the gut wall. After absorption aspirin is rapidly converted to salicylate but during the first 20 minutes following oral administration, aspirin is the predominant form of the drug in the plasma. Aspirin is 80% to 90% bound to plasma proteins and is widely distributed; its volume of distribution is reported to be 170 mL per Kg body weight in adults. As plasma-drug concentrations increase, the binding sites on the proteins become saturated and the volume of distribution increases. Both aspirin and salicylate have pharmacological activity; only aspirin has an anti-platelet effect. Salicylate appears in breast milk and crosses the placenta.
Aspirin is used for the prophylaxis of cerebrovascular disease or myocardial infarction or for the secondary prevention of thrombotic cerebrovascular or cardiovascular disease. It is also used for pain, in musculoskeletal conditions, headache, dysmenorrhea, pyrexia, and fever.
Prevention of Myocardial Infarction and stroke: 75 mg to 100 mg.
As Analgesic/Antipyretic: 300 mg to 900 mg every 4 to 6 hours when necessary to a maximum of 4 g daily or as prescribed by the physician.
Children and adolescents under 16 years of age and in breast-feeding mothers because of risk of Reye's syndrome.
With previous or active peptic ulceration.
Haemophilia; Not for treatment of gout; With history of hypersensitivity to Aspirin or any other NSAIDs.
Aspirin should be cautiously employed, if at all, in patients prone to dyspepsia or known to have a lesion of the gastric mucosa.
The most common adverse effects occurring with therapeutic doses of aspirin are gastrointestinal disturbances such as nausea, dyspepsia and vomiting. Aspirin may provoke various reactions including urticaria and other skin eruptions, angioedema, rhinitis and severe, even fatal paroxysmal bronchospasm and dyspnea especially to those with asthma, chronic urticaria or chronic rhinitis. Aspirin increases bleeding time, decreases platelet adhesiveness and, in large doses, may cause hypoprothrombinemia. Persons sensitive to aspirin may exhibit cross-sensitivity to other NSAIDs. Symptoms of salicylism include dizziness, tinnitus, deafness, sweating, nausea and vomiting, headache and mental confusion. In children, the use of aspirin has been implicated in some cases of Reye's syndrome.
Effect of aspirin on the gastrointestinal tract (GIT) are enhanced by alcohol. Aspirin may enhance the activity of coumarin anticoagulants, sulphonylurea, hypoglycemic agents, methotrexate, phenytoin and valproic acid. Aspirin diminishes the effects of uricosurics such probenecid and sulphinpyrazone.
Store at temperatures not exceeding 30°C.
B01AC06 - acetylsalicylic acid ; Belongs to the class of platelet aggregation inhibitors excluding heparin. Used in the treatment of thrombosis.